Compare Novavax Inc (NVAX) vs Zillow Group Inc Class C (Z) Price & Performance

Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.

The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.

Zillow Group (Z) is trading at $32.36, down 6.45% over 24 hours, with a bearish technical signal. The stock shows mixed fundamentals: a high P/E of 139.74 reflects growth expectations, but net income margin is thin at 1.96%. Recent Q2 2026 earnings beat expectations, and revenue growth is projected from $2.6B in 2025 to $2.8B in 2026. News highlights include an FTC settlement and expansion of rental services.

The outlook is cautiously optimistic. Analyst consensus price target is $52.00, implying significant upside, but risks include a challenging housing market, ongoing profitability concerns, and recent legal settlements. The stock's current price near support at $32 suggests potential stability if fundamentals improve.